A simple reverse phase analytical technique was established for quantification of single and combinational drugs. A simple, economic, accurate reverse phase isocractic RP-HPLC method was established for the simultaneous quantification of Sofosbuvir, Velpatasvir and Voxilaprevir in bulk and tablet dosage forms. The estimation was done by using Discovery C18 (250×4.6mm,5µm) column with the flow rate of 1.0 ml/min, at λmax 260 nm. Solution-A was 0.1% OPA (pH 1.8) in water and solution -B was Acetonitrile (mobile phase: solution A: solution B, 50:50 v/v). The Rt for Sofosbuvir, Velpatasvir and Voxilaprevir is 2.458 min., 3.282 min and 4.003 min. respectively. The system was established and validated as per ICH guidelines.
INTRODUCTION
Hepatitis C virus was found to be a commonly attacking disease to human beings and was increased day by day. The literature reveals that 72% of the patients were suffered from chronic HCV. In early stage 75% to 85% of the liver is persisted with the virus. These defects have been treated by use of an oral form of these combinational drugs respectively. Sofosbuvir ( Fig.-1a) is an antiviral drug in the treatment of chronic hepatitis C virus. It is chemically isopropyl (2s)-2[[[(2R,3R,4R,5R)-5-(2,4-dioxop[yrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetra hydro furan-2-yl] methoxy-phenoxy-phosphoryl] amino] propanoate. Mainly Sofosbuvir is activated in the liver to the triphosphate by hydrolysis of the carboxylate ester 1 . Velpatasvir (Fig.-1b) is an NS5A inhibitor which acts on hepatitis C virus. Velpatasvir is chemically Methyl
{( 2 S ) -1 -[ ( 2S, 5S) -2 -(9 -{ 2 -[(2S ,4S) -1 -{(2R) -2 -[(methoxycarbonyl) amino] -2 -phenylacetyl}
-3-methyl-1-oxo-2-butanyl} carbamate used as an anti-cholinergic and anti-spasmodic 2 . Voxilaprevir (Fig.-1c) it is also a protease inhibitor and acts as a transporter of polypeptide. Voxilaprevir is chemically (1R,18R,20R,24S,27S,28S)-N-[(1R,2R)-2-(Difluoromethyl)-1-{[(1-methylcyclopropyl) sulfonyl] carbamoyl} cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22, 25-dioxo-2,21-dioxa-4,11,23,26-tetra aza penta cyclo nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide 3 . Some of the literature was available for the combination of Sofosbuvir and Velpatasvir. [4] [5] [6] [7] [8] No literature available for the estimation of Sofosbuvir, Velpatasvir and Voxilaprevir in a combined dosage form. Sofosbuvir(400mg), Velpatasvir(100mg) and Voxilaprevir(100mg) were available in a mixed dose form of VOSEVI. The US FDA was approved in 2017. The HPLC technique was used for the development and validation of combinational drugs were reported [4] [5] [6] [7] [8] [9] . But no method was found for the estimation of 
EXPERIMENTAL

Reagents and Chemicals
The three drug samples were gifted from Spectrum labs Hyderabad. HPLC grade solvents and chemicals were used for the study. The marketed form of Vosevi was purchased from Ankur pharmacy Bangalore. The OPA and Acetonitrile were supplied by Merck [India] Pvt., Ltd., Mumbai.
Instrumentation
The HPLC system module 2965, Empower2 software and 2996 module of PDA detector, a quaternary gradient delivery pump, automatic sample injector and a column Discovery C 18(250×4.6mm,2.5µm) respectively. Electronic balance, Sonicator (ultra-sonic cleaner power sonic 420), PH meter, water bath and other glassware were used for the present investigation.
Chromatographic Conditions
Discovery C18(250×4.6mm,2.5µm) column was operated at 30 0 C temperature with a flow rate of 1.0 ml/min., at fixed λmax 260 nm. Solution-A was 0.1% OPA (pH 1. 
Preparation of Mobile Phase
Mixture of 500ml (50%) OPA buffer (pH 1.8) and 500ml of (50%) ACN were mixed and degassed to sonicate it. The filtration was done under vacuum with 0.45 µ filter paper.
Preparation of Diluent
Water and ACN were taken as a diluent. (50:50).
Preparation of Standard Solution
Working standards of (40mg) Sofosbuvir, (10mg) Velpatasvir and (10mg) Voxilaprevir were weighed and taken into three-separate 50ml dry volumetric flasks. 5ml of the diluent was added and made up to the mark. From the prepared solutions, 1ml of each solution was added to a 10ml flask to obtain a mixed standard solution. (This is a 100% for various experimental procedures)
Preparation of Sample Solution
Five tablets were crushed homogenously to prepare a powder equivalent to one tablet and taken in a 100ml volumetric flask. 60ml of diluent was added to the powder, diluted, made up to the mark and sonicated for 25min.Then 1ml was taken in 10ml flask diluted up to the mark, filter through the 0.45µ filter.
RESULTS AND DISCUSSION
Method Development
Initially, the method trails were performed with acidic and basic phosphate buffer, acetonitrile and methanol by using gradient and isocratic mode buffer, which was analyzed with C4, C8, C18, cyano and Amino columns. Finally, the separation was arrived on a Discovery C18 (250×4.6mm, 5µ) column with the flow rate of 1.0 ml/min, at 260 nm wavelength. Solution-A was 0.1% OPA (pH 1.8) in water and solution -B was Acetonitrile (mobile phase: solution A: solution B, 50:50 v/v).
Method Validation Specificity
Drug -Drug interaction (or) drug-excipient interaction was known through this parameter. The mixture of sample and standard drugs were separated. No interference of the diluent at the Rt values of three drugs. The HPLC chromatograms are shown in Fig.-2 and 3 .
Linearity
The linearity study was done by injecting the different concentrations (50% -150%) of the drugs. From the linearity curve the correlation coefficient was found to be less than 1.0. The results were incorporated in Table- 1.The linearity plots were shown in Fig.-4 . 
Accuracy
The recovery study was done by standard addition method for three drugs at 50%,75% and 150% level. The results were given in Table- 2. 
Method Precision
Six different sample solutions were prepared from the commercial tablets and injected into HPLC. The %RSD was below 1% for all drugs. The values were incorporated in Tables-3 to 5 . 
Intermediate Precision
The %RSD of the area and Rt values were analyzed for two different analysts and results were mentioned in Table-6 . It is evident that the method is rugged from the above data. VOX  SOF  VEL  VOX  1  502185  283583  322180  506002  283342  320445  2  503811  282997  323302  505616  283680  325732  3  500040  284718  323076  500127  285401 
LOD and LOQ
The LOD and LOQ were calculated from the linearity curve method and presented in Table-7 . 
Robustness
No changes were observed in chromatograms when changing the flow rate, the concentration of mobile phase and temperature. Hence the method was robust. The results were shown in Table- 8. 
System Suitability
The system suitability checked for the developed method were tailing factor, retention time and theoretical plates were observed within the acceptance criteria, presented in Table-9 . 
CONCLUSION
The present study concludes that the developed method was simple, selective and reproducible with shorter time. Hence this investigation was suitable for the estimation of Sofosbuvir, Velpatasvir and Voxilaprevir simultaneously. The present method was accurate, precise and Robust. This method can apply for releasing routine, quality control and stability indicating studies.
